jmt202
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 23, 2024 (NCT06564467)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
FGFR1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07140809 | Phase 1/Phase 2 (Phase 2) | Sep 9, 2025 | Shanghai JMT-Bio Inc. |
| NCT06564467 | Phase 1 | Jul 23, 2024 | Peking University, Shanghai JMT-Bio Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai JMT-Bio Inc. | For profit | 2 | 2 | 2 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1